论文部分内容阅读
红细胞生成素在造血调节因子中,红细胞生成素(EPO)从1960年一发现就例外的证实具有刺激活体内增加红细胞生成的功能。人EPOCDNA 克隆化以及随后的重组产品的大量生产使有可能进行临床研究。以往的报道集中在晚期肾脏病人,这类病人成为严重的输血依赖性贫血,因EPO 主要由肾脏分泌。每周三次静注重组EPO(50～500U/kg)可使红细胞压积(PCV)逐渐升高,其升高的速度与剂量有关,用最高剂量时,PCV 于六周内
Erythropoietin Among the hematopoietic regulators, erythropoietin (EPO) has been shown to stimulate erythropoiesis in vivo in vivo as soon as it was discovered in 1960. Cloning of human EPOC DNA and the subsequent mass production of recombinant products make it possible to conduct clinical studies. Previous reports have focused on patients with advanced renal disease, such patients become severe transfusion-dependent anemia, due to the secretion of EPO mainly by the kidneys. Intravenous injection of recombinant EPO (50-500 U / kg) three times a week resulted in a gradual increase in hematocrit (PCV), and its rate of increase was dose-dependent. At the highest dose, PCV was within six weeks